NCT01750294已完成4 期
A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Change of Systolic Ambulatory Blood Pressure From Baseline to 12 Weeks
研究概览
简要总结
It is estimated that in the United States there are approximately 8 million individuals with moderate to severe chronic kidney disease (CKD), not on dialysis. Volume expansion plays an important role in the pathogenesis of hypertension in patients with CKD. For this pilot study, the investigators hypothesize that administration of chlorthalidone among patients with moderate to severe CKD will improve blood pressure (BP).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age greater than 18 years.
- •Estimated glomerular filtration rate (eGFR) ≤ 45 ml/min/1.73m2 but ≥20 mL/min/1.73m
- •Poorly controlled blood pressure by 24-hour ambulatory blood pressure (BP) monitoring.
- •Treated hypertension: use of at least one antihypertensive drug. One of the drugs should be either an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). If these are contraindicated then use of a beta-blocker is required.
排除标准
- •Use of thiazide or thiazide-like drugs in the previous 3 months.
- •Use of furosemide in a dose >200 mg/d.
- •Ambulatory BP of either ≥160 systolic or ≥100 mmHg by 24-hour ambulatory BP monitoring.
- •Expected to receive renal replacement therapy within the next 3 months.
- •Vascular event such as myocardial infarction, heart failure hospitalization, or stroke within 3 months prior to randomization.
- •Pregnant or breastfeeding women or women who are planning to become pregnant or those not using a reliable form of contraception (oral contraceptives. condoms and diaphragms will be considered reliable).
- •Known hypersensitivity to thiazide or sulfa drugs.
- •Organ transplant recipient or therapy with immunosuppressive agents. Nasal or inhaled corticosteroids will be permitted.
结局指标
主要结局
Change of Systolic Ambulatory Blood Pressure From Baseline to 12 Weeks
时间窗: Baseline and 12 weeks after intervention
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Efficacy and Safety Study of Aplindore in Patients With Restless Legs SyndromeRestless Legs SyndromeNCT00834327Neurogen Corporation230
进行中（未招募）
不适用
A Clinical Trial for Self-Injurious BehaviorSelf-Injurious BehaviorNCT03995966Hugo W. Moser Research Institute at Kennedy Krieger, Inc.16
撤回
早期 1 期
Theophylline for Depression StudyDepressionNCT04309877University of California, Los Angeles
已完成
4 期
INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 DiabetesType 2 DiabetesNCT01087567Ohio University23
终止
3 期
Tapered Warfarin or Interrupted Warfarin With Heparin Bridging for Pacemaker or Defibrillator ImplantationHemorrhageCardiac ArrhythmiasThromboembolismNCT02094157McMaster University173